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Abstract
Background and Objectives—A previously published study of antiretroviral
pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing
degrees of female genital tract penetration among antiretrovirals. These blood plasma (BP) and
cervicovaginal fluid (CVF) data were co-modelled for four antiretrovirals with varying CVF
exposures.
Methods—Six paired BP and CVF samples were collected over 24 h, and antiretroviral
concentrations determined using validated liquid chromatography (LC) with UV detection or LC-
mass spectrometry analytical methods. For each antiretroviral, a BP model was fit using Bayesian
estimation (ADAPT5), followed by addition of a CVF model. The final model was chosen based
on graphical and statistical output, and then non-linear mixed-effects modelling using S-ADAPT
was performed. Population mean parameters and their variability are reported. Model-predicated
area under the concentration-time curve during the dosing interval (AUCτ) and exposure ratios of
CVF AUCτ:BP AUCτ were calculated for each drug.
Results—The base model uses first-order absorption with a lag time, a two-compartment model,
and a series of transit compartments that transfer the drug from BP to CVF. Protein-unbound drug
transfers into CVF for efavirenz and atazanavir; total drug transfers for lamivudine and tenofovir.
CVF follows a one-compartment model for efavirenz and atazanavir, and a two-compartment
Corresponding author/reprints: Julie B. Dumond, 3320 Kerr Hall, CB 7569, UNC Eshelman School of Pharmacy, Chapel Hill, NC
27599-7569, USA, jdumond@unc.edu.
Conflicts of Interest
A.D.M. Kashuba has received research funding and speaking honoraria from Bristol-Myers Squibb, Merck, Gilead and
GlaxoSmithKline. K.B. Patterson has received research funding from GlaxoSmithKline. The other authors have no conflicts of interest
that are directly relevant to the content of this study.
Author Contributions
J.B. Dumond: data collection, data analysis, including the original publication and current modelling applications, primary author of
the original and current manuscript. M.R. Nicol: data analysis of atazanavir, critical review of the manuscript. R.N. Kendrick: data
analysis of lamivudine, critical review of the manuscript. S.M. Garonzik: data analysis of the current modelling applications, critical
review of the manuscript. K.B. Patterson: data collection, critical review of the original and current manuscript. M.S. Cohen:
conceptual design of original study, critical review of the original and current manuscript. A. Forrest: data analysis of the current
modelling applications, critical review of the manuscript. A.D.M. Kashuba: conceptual design of original study, data collection, data
analysis of the original publication, funding of the original study, critical review of the original and current manuscript.
NIH Public Access
Author Manuscript
Clin Pharmacokinet. Author manuscript; available in PMC 2013 December 01.
Published in final edited form as:










model for lamivudine and tenofovir. As expected, inter-individual variability was high. Model-
predicted CVF AUCτ:BP AUCτ ratios are consistent with published results.
Conclusions—This is the first pharmacokinetic modelling of antiretroviral disposition in BP
and CVF. These models will be further refined with tissue data, and used in clinical trials
simulations to inform future studies of HIV pre-exposure prophylaxis in women.
Keywords
HIV-infections; pharmacokinetics; pharmacokinetic-modelling; population-pharmacokinetics;
antiretrovirals; atazanavir; efavirenz; lamivudine; tenofovir
1. Introduction
With the availability of potent antiretroviral drugs, and no current HIV vaccine, the use of
antiretrovirals as a prevention tool is an attractive option to reduce the global HIV epidemic.
Recent data demonstrate that treating the index case with antiretrovirals reduces
transmission by 96 % in heterosexual serodiscordant couples [1]. By inference, this is likely
due to reducing HIV RNA in the genital tract by reducing HIV RNA in the blood to <400
copies/mL [2–4]. However, factors such as sexually transmitted infections and increased
inflammation from non-infectious causes can result in HIV RNA discordance between blood
and genital tract secretions [5–8]. It has also been suggested that the genital tract may be a
sequestered site for HIV replication [9, 10]. Therefore, inadequate penetration of
antiretrovirals into the genital tract has the potential for incomplete suppression of HIV
RNA replication, the development of drug resistance, and an increase in the risk of sexual
HIV transmission. In both the male and female genital tract, antiretroviral concentrations
vary from a fraction of blood exposure to exposures several-fold higher than blood [11, 12].
The mechanism for this behaviour is unclear [12]. Pharmacokinetic modelling is a potential
tool for understanding, and hence optimizing, drug behaviour in the genital tract.
This analysis extends previously published non-compartmental analysis and comparison of
exposure in cervicovaginal fluid (CVF) relative to blood plasma (BP) for several
antiretrovirals [13]. Agents were selected based on the number of women receiving the drug,
and to represent varying penetration in CVF. Efavirenz represents a highly protein-bound
(99.9 %) non-nucleoside reverse transcriptase inhibitor [14] with very low penetration into
CVF. Among the protease inhibitors studied, atazanavir represents a moderately penetrative
drug with high protein binding (86 %) [15]. Tenofovir and lamivudine, both nucleoside/
nucleotide reverse transcriptase inhibitors, have low protein binding (<7 [16] and 40 % [17],
respectively). Tenofovir shows similar exposures to BP in CVF, while lamivudine
demonstrates higher exposures [13].
The aim of the current project is to develop a framework for future analysis of oral
antiretroviral regimens to prevent heterosexual HIV transmission. Combining these models
with concentration targets of efficacy will allow optimization of doses and dosing
frequencies for antiretroviral prevention interventions.
2. Methods
2.1 Study Design and Conduct
A detailed description of study methods has been previously published [13]. Briefly, 27 HIV-
infected pre-menopausal women without evidence of a sexually transmitted infection and
initiating a new provider-selected antiretroviral regimen at the University of North Carolina
(UNC) at Chapel Hill (Chapel Hill, NC, USA) were enrolled. Pharmacokinetic sampling
was conducted around the first dose (FD) of the new regimen and approximately 30 days
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later, from November 2002 to May 2006. The multiple-dose (MD) visit was added after
several subjects completed the protocol, and therefore not all subjects contribute data from
both visits. Paired BP and directly aspirated CVF samples were taken pre-dose (time = 0),
and 2, 4, 6, 12 and 24 h after observed dosing of the antiretroviral regimen. The study
protocol was approved by the UNC Biomedical Institutional Review Board, and all subjects
provided informed consent prior to study interventions. Drug concentrations were
determined using high-performance liquid chromatography (HPLC) with UV detection or
HPLC-tandem mass spectrometry methods available in the Center for AIDS Research
Clinical Pharmacology and Analytical Chemistry Laboratory [18–22]. For the drugs of
interest, the lower limit of quantitation (LLQ) in BP was 10 μg/L for efavirenz, lamivudine
and tenofovir and 25 μg/L for atazanavir. In CVF, the LLQ was 5 μg/L for efavirenz,
lamivudine and atazanavir, and 10 μg/L for tenofovir. Inter-day and intra-day percentage
coefficient of variation (CV%) values of all assays were <15 %.
2.2 Pharmacokinetic Analysis
2.2.1 Structural Model Development—To develop the structural model for each drug,
individual subject modelling was performed using the maximum a posteriori probability
(MAP) Bayesian estimator [23] in ADAPT5 software (Biomedical Simulations Resource,
Los Angeles, CA, USA) [24]. Prior means and variability around those means for BP were
initially obtained from the literature for each drug [25–28]. Model development began with
the first-dose BP data; once a satisfactory model [as assessed by Akaike’s Information
Criterion (AIC) [29] and visual inspection of observed vs. fitted values] was found, Bayesian
priors were refined and the CVF compartment was added to the model using empirical
Bayesian priors. After each round of modelling, Bayesian priors were updated to reflect
mean parameter and variance estimates from the data (iterative two-stage analysis). After
first-dose BP and CVF were co-modelled, multiple dose data were added (BP and CVF
added simultaneously). Since full 30-day dosing histories were not available, datasets were
constructed using the limited available adherence and timing data with a variable number of
doses between visits for each subject. For all drugs, multiple-dose data required a second set
of model parameters to adequately describe the data (allowing for between-occasion
variability).
Additive plus proportional residual error variance models, with the LLQ of the assay as the
standard deviation intercept and twice the CV% of the assay as the initial estimate for the
standard deviation slope, were used throughout; intercept values were fixed, and slope
values were estimated. Through the in-built functionality in ADAPT5, the Beal M3 method
for inclusion of data below the limit of quantitation (BLQ) was invoked [30]. A log-normal
distribution was assumed for all estimated parameters.
2.2.2 Population Modelling Methods—After structural model development in
ADAPT5, non-linear mixed effects modelling using the Monte-Carlo parametric expectation
maximization (MCPEM, pmethod 4) algorithm of S-ADAPT with the S-ADAPT TRAN
pre- and post-processing package [31, 32] was used to obtain population parameter estimates,
inter-individual variability and estimates of parameter precision. Simplified datasets for each
drug were constructed as follows to increase the speed of each modelling run. While still
maintaining the timing of the samples around the dose of the drug, several days of dosing
were administered after the first dose, and were uniform across subjects. Dosing allowed the
drug to achieve steady-state conditions, based on five BP half-lives; this was 96 h of dosing
for lamivudine and tenofovir, and 216 h of dosing for efavirenz and atazanavir. Following
ADAPT5 results, parameters other than distributional clearances/rate constants were
allowed to differ between visits, and were reduced to a single parameter when possible,
based on similarities in mean values, post hoc individual estimates and inter-individual
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variability. Additionally, the between-occasion variability function in S-ADAPT was used,
if appropriate. To account for two values for each parameter depending on the study period,
the individual subject datasets were coded into groups, with group 1 values applied to the
first dose, and group 2 values applied to all subsequent doses and the second
pharmacokinetic visit. For initial model runs, 200 iterations were performed, with 400
iterations used for the final model.
In the residual error variance models, only the slope of the BP error variance model was
estimated (SDSLBP); the intercepts were fixed at the LLQ and the CVF slope at twice the
estimated CV% of the assay (0.3), as the model would not run with estimation of all error
model parameters, and ADAPT5-estimated CVF error slopes were high for each drug
(approximately 0.6). The Beal M3 method for BLQ data was invoked [30]. A log-normal
distribution was assumed for all estimated parameters, and a full covariance matrix was
used. Models were compared using the likelihood ratio test; decreases in objective function
value were considered significant if they exceeded the critical value corresponding to a
significance level of 0.05. Plots of the individual fitted concentrations compared with
observed concentrations, weighted residuals, and individual subject observed versus
predicted time-concentration profiles [33] were also examined to select the final model.
Monte-Carlo simulations of 1,000 subjects using the final model parameter means and
covariance matrix were performed in ADAPT5 for each drug to produce visual predictive
checks (VPCs). VPC graphs were constructed using the 5th–95th percentiles and median
values of the simulated data with SigmaPlot™ 11 (Systat Software Inc., Chicago, IL, USA).
2.2.3 Model-Predicted Cervicovaginal Fluid (CVF):Blood Plasma (BP) Area
Under the Plasma Concentration-Time Curve (AUC) Ratios—To compare
modelling results with the non-compartmental analysis-derived CVF exposure ratios for
each drug, simulations in ADAPT5 were performed using subject post hoc estimates
(generated using the mean of the Bayesian distribution) to generate an area under the
concentration-time curve (AUC) during the dosing interval (AUCτ) in BP and CVF at both
first and multiple doses by numerically integrating the relevant differential equations. As
one model employed the protein-unbound fraction in blood (fu) to control drug transfer into
the CVF, BP AUCτ values were multiplied by the estimated fu and compared to the CVF
AUCτ estimate [14–17]. Correcting for protein binding in blood has been used in studies of
drug penetration into cerebrospinal fluid (CSF) to assess measured CSF exposure compared
to the theoretical amount of drug available (fu) to cross membranes [2, 9, 29]. To calculate
median CVF:BP ratios, individual subject ratios were summarized.
3. Results
3.1 Subject Demographics
Subject demographics by drug studied are presented in Table 1. As typical antiretroviral
regimens contain at least three drugs, each group of women receiving a given drug overlaps
with women receiving other drugs. The population chosen for modelling represents 25 of the
27 women in the original non-compartmental analysis. Overall, the study population was
predominantly African American (17/25 subjects), approaching middle-age (median age of
35 years) and antiretroviral-experienced (18/25 subjects). The median CD4+ cell count was
269 cells/mm3 at the first-dose visit. The median BP log HIV RNA concentration was 4.71
(51,209 copies/mL) at first dose, and ranged from the lower limit to the upper limit of the
assay (<50 to >750,000 copies/mL). The median CVF log HIV RNA concentration was 4.2
(16,000 copies/mL), and ranged from the lower limit of the assay (<400 copies/mL) to
1,300,000 copies/mL. The median time between the first and second pharmacokinetic visits
was 32.5 days (range: 20–154 days).
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3.2.1 Structural Models—The structural models for each drug are depicted in Fig. 1. For
efavirenz and atazanavir, a similar structural model was used, with atazanavir having one
fewer absorptive compartments. A two-compartment model (central volume [V1], peripheral
volume [V2]) with first-order elimination (total BP clearance [CLt]) and absorption via the
first-order absorption rate constant ka and transit compartments between the site of drug
administration and the central compartment was used to describe the BP data. Transfer of
drug to the CVF occurred from the central compartment through a transit compartment via
the rate constant tau; the amount of drug entering the CVF was the concentration in the BP
central compartment multiplied by the estimated fu (0.01 for efavirenz, 0.14 for atazanavir).
A one-compartment model with first-order elimination (CVF clearance [CLg]) was used to
describe drug behaviour in the genital tract. The volume of the genital tract compartment
was assumed to be 1 L to simplify the differential equations.
The efavirenz/atazanavir model in BP was utilized for lamivudine and tenofovir. However,
the efavirenz/atazanavir model in CVF did not provide satisfactory fits of the lamivudine/
tenofovir data in CVF. Therefore, an alternate forcing function of drug transfer from BP to
CVF was employed. The controlling factor of fu was removed, and clearance from the
central compartment (CLt) moved drug into the CVF (Fig. 1c–d). In this model, volume of
the CVF was not assumed to be 1 L, and was added as an estimated parameter (Vg) since a
two-compartment model was used to describe the CVF disposition. Drug was cleared from
Vg by CLg, and moved between the first and second CVF compartments via the first-order
rate constants kg12 and kg21. For tenofovir, a dose of 136 mg was used, as this is the amount
of tenofovir in the 300 mg dose of tenofovir disoproxil fumarate.
Model differential equations are available in the Online Resource.
3.2.2 Final Population Model Selection—Over multiple runs, we attempted to reduce
the number of parameters from two parameter sets for the BP V1, BP V2, CLt, CLg, tau and
ka. Table 2 describes the changes in minimum objective function value for these candidate
models; for all drugs, a model with one set of parameters for both visits was the basis for
comparison to models with separate parameters for each visit. Based on change in objective
function value, a model using separate values for CLt, CLg, tau and ka was selected as the
final model for efavirenz, lamivudine and tenofovir; a model using separate values for Clg
and tau was selected for atazanavir. Final parameter estimates, inter-individual variability
(CV%), and estimates of parameter precision (percentage standard error [SE%]) are
presented in Table 3.
3.2.3 Individual Drug Model Fittings
3.2.3.1 Efavirenz: For efavirenz, six of ten women provided data at both visits, and all
subjects received the standard dose of 600 mg by mouth daily in combination with other
agents. In the efavirenz data set, 37 samples (19 % of data points) were BLQ. In the
calculation of concentrations in CVF, the differing amounts of sample collected were
accounted for with a multiplication factor, and because of this and the very low
concentrations of efavirenz in CVF, an effective BLQ of 0.1 μg/L in CVF was used in the
error model rather than the LLQ of the assay.
In Table 3, inter-individual variability was highest (>100 CV%) for parameters related to
absorption (ka,MD) and drug transfer from BP to CVF (tauFD, tauMD), and these are also the
least precise of the estimates. The individual predicted concentrations versus observed
concentration plots for BP and CVF on a log scale are shown in Fig. 2a. For BP, the model
over-predicted several low observed concentrations and under-predicted one high observed
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concentration. VPCs for BP and CVF are shown in Fig. 3 and are consistent with the
individual fitted versus observed concentration plots. The confidence envelopes included
>90 % of the observations, suggesting imprecision in the fitted parameters; the full
covariance matrix was not able to be used in generating these plots.
3.2.3.2 Atazanavir: For this drug, all eight women provided data at both visits. Seven
subjects received atazanavir 300 mg in combination with ritonavir 100 mg as a
pharmacokinetic boosting agent; one subject received atazanavir 400 mg daily without
ritonavir (unboosted). In the atazanavir dataset, 29 samples (15 % of data points) were BLQ.
In Table 3, multiple parameters have variability estimates >100 %, suggesting some over-
parameterization of the model. The individual fitted versus observed concentration plots for
BP and CVF are shown in Fig. 2b, showing some over-prediction of the data, particularly in
CVF. VPCs are shown in Fig. 4. Again, there was >90 % coverage within the 90 %
confidence envelope; the full covariance matrix was not able to be used in generating these
plots. No significant differences were noted when the subject receiving unboosted atazanavir
was excluded.
3.2.3.3 Lamivudine: Ten subjects received lamivudine 150 mg twice daily; five of those
subjects provided data at both visits. The remaining nine subjects received lamivudine 300
mg once daily, and eight of those subjects provided data at both visits. CVF exposure ratios
did not differ by regimen in the original analysis [13], and therefore the dosing regimens
were combined for modelling. The complete lamivudine dataset contained 43 samples (12 %
of data points) that were BLQ, 21 (48 %) of those from subjects receiving twice daily doses.
In Table 3, the parameters with the highest inter-individual variability were those of the
CVF disposition, likely related to the highly variable nature of CVF concentrations and
some model over-parameterization. The individual fitted versus observed concentration
plots for BP and CVF are shown in Fig. 2c; the model predicts blood concentrations well,
with over-prediction of several CVF observations. VPCs for subjects who received the drug
once daily are shown in Fig. 5. Here, <90 % of the observed data were within the confidence
envelope; parameters with >80 % correlation were included in the covariance matrix.
Results were similar for those receiving the drug twice daily (data not shown).
3.2.3.4 Tenofovir: For this drug, ten of 15 women provided data at both visits, and all
subjects received the standard dose of 300 mg of tenofovir disoproxil fumarate. The
complete tenofovir dataset contained 81 samples (27 % of the data points) that were
considered BLQ.
In Table 3, CLg and CLt increased by 27 and 29 L/h, respectively, between visits and CV%
was >100 % for several parameters, and particularly high for kg12. Large increases in
tenofovir clearance terms has been previously reported [34]. Most, but not all, subjects
showed lower AIC values for the two-compartment CVF model, which increased the
variability in kg12. The individual fitted versus observed concentration plots for BP and CVF
are shown in Fig. 2d; for both BP and CVF, the model over-predicts lower BP and CVF
observations. VPCs for BP and CVF are shown in Fig. 6 and are reflective of the model
over-prediction, particularly in CVF after multiple doses.
3.3 Model-Predicted CVF:BP AUC ratios
Model-predicted AUCτ values, ratios of AUCτ CVF:BP, and CVF:BP using unbound (free)
BP AUCτ (fAUCτ) are presented in Table 4. For each drug, CVF:BP ratios were similar to
previously published values. Ratios generated by using fAUCτ were different, as would be
predicted by the range of fu. For efavirenz, the AUCτ CVF:fAUCτ BP ratios of 0.53 and
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0.66 at first and multiple doses, respectively, indicate that approximately half of the
unbound drug appears in the CVF. For atazanavir, the AUCτ CVF:fAUCτ BP ratios >1
indicate that unbound drug may concentrate in the genital tract. Less of an effect is seen for
lamivudine and tenofovir, which have lower protein binding. Lamivudine demonstrated high
penetration in CVF (ratios >4) and tenofovir demonstrated exposure in CVF similar to blood
(ratios of approximately 1.6 for first and multiple doses, regardless of protein binding).
4. Discussion
Using data from a comprehensive investigation of antiretroviral pharmacokinetics in HIV-
infected pre-menopausal women, these are the first pharmacokinetic models to describe the
movement of drug from BP to CVF for efavirenz, atazanavir, lamivudine and tenofovir.
Depending on the drug, either the unbound fraction in blood (efavirenz, atazanavir) or total
drug clearance (lamivudine, tenofovir) was the forcing function for drug distribution from
BP to CVF. This difference in model structure reflects the degree of protein binding in blood
for these drugs, with highly bound drugs limited in penetration by the unbound fraction. We
attempted to find a common model to accommodate the transfer from BP to CVF, but model
predictions for efavirenz using the total-drug model resulted in unlikely parameter estimates
for CVF parameters (i.e. Vg values >1,000 L), and V2 estimates increased by an order of
magnitude. For atazanavir, AIC values in ADAPT5 were lower for most subjects using the
unbound-fraction model. Lamivudine profiles were not well fitted with the unbound-fraction
model, and for tenofovir, protein binding is so low (<7 %) that only the total-drug model
was considered. Drug disposition in CVF also differed between efavirenz/atazanavir and
tenofovir/lamivudine, with tenofovir/lamivudine best modelled using a two-compartment
CVF model. This is consistent with behaviour recently observed in healthy volunteers
receiving tenofovir, which suggests a long-lived cellular compartment with equilibrium
between tenofovir and its diphosphate metabolite [35]. Equivalent data do not exist for
lamivudine; however, emtricitabine, a fluorinated analogue of lamivudine, was co-
administered with tenofovir and demonstrated similar behaviour [35].
In assessing the model-predicted AUCτ CVF:fAUCτ BP ratios for efavirenz and atazanavir
and total CVF concentrations, 66 of 68 CVF samples with detectable efavirenz
concentrations (97 %) were above the concentration producing 50 % inhibition of wild-type
HIV virus (IC50) of 0.51 ng/mL [36] and 71 of 75 CVF samples with detectable atazanavir
concentrations (95 %) were above the IC50 of 11 ng/mL [15]. Although a relationship
between CVF penetration and protein binding was seen here, this does not universally hold
true for other drugs in CVF [12]. Additionally, the protein binding of these drugs in the CVF
is unknown, and as albumin and α1-acid glycoprotein concentrations are <1 % of plasma
values [37], less drug may be bound in CVF, as has been demonstrated for maraviroc [38],
potentially making more drug available for pharmacological action.
Pharmacokinetic modelling of antiretrovirals can be challenging, given multiple drugs used
in combination, significant drug-drug interactions among antiretrovirals in a regimen as well
as between antiretrovirals and drugs to treat co-morbid conditions, and the inherent high
inter-individual variability in pharmacokinetics. This phenomenon has been well-
documented for antiretrovirals in BP [39]. CVF pharmacokinetics appear to have even
greater variability for the following reasons [11]. First, collection methods are more complex
and less consistent from subject to subject for CVF. Second, drug-drug interactions among
the antiretrovirals in a given subject’s regimen were not accounted for in the models. Third,
relatively little is known about intra-individual variability in CVF; however, intra-individual
variability of antiretrovirals in BP is known to be quite high, ranging from 25 % for
nucleoside agents up to 76 % for indinavir, a protease inhibitor [39, 40]. This may partially
explain the need for separate parameters to describe both study visits simultaneously, and
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the high variability in the estimated parameters. Finally, these drugs are also substrates of
several drug transporters that may be relevant for controlling disposition into the genital
tract [11].
Several limitations were present in the data. For each drug, several subjects in the data had
difficult-to-fit concentration-time profiles, with no consistent pattern among subjects.
Therefore, structural amendments to the models to improve fits were not possible. The large
percentage of BLQ data also decreased the available data for model fitting. Previous reports
in the literature suggest auto-induction by efavirenz during the first month of treatment [41];
however, this phenomenon was not observed here, and is a potential consequence of these
limitations. Adding covariates to explain inter-individual variability is commonly employed
in population pharmacokinetics, but was not possible here, given the homogeneity of the
subject population. Each drug had limited representation: most participants were African
American with a narrow range of ages. Although there was wide variability in bodyweight,
bodyweight did not demonstrate a relationship with volume or clearance in exploratory data
analysis (data not shown).
5. Conclusion
The presented pharmacokinetic models for efavirenz, atazanavir, lamivudine and tenofovir
provided some insight into drug disposition into CVF. Using non-linear mixed-effects
modelling, relatively sparse datasets were fitted to two basic models. High inter- and intra-
individual variability were expected with antiretroviral drugs, particularly when measuring
CVF concentrations, and pharmacokinetic parameter estimates show high inter-individual
variability. Three of the four drugs required models using separate clearance, absorption and
transfer terms for each dosing interval to best describe the data. These models provide the
basis for future work in establishing relationships between drug concentrations in mucosal
tissues and HIV replication. Moreover, this type of modelling will have increasing economic
importance in optimizing antiretroviral therapy as treatment and prevention strategies move
forward in limited resource environments.
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Model schematics for efavirenz (a), atazanavir (b), lamivudine (c) and tenofovir (d). BP
blood plasma, Cn compartment number n, CLd distributional clearance in blood plasma, CLg
CVF clearance, CLt total BP clearance, CVF cervicovaginal fluid, ka first-order absorption
rate constant, kgxy transfer rate constant from CVF compartment x to y, tau transit
compartment transfer rate constant, V1 apparent volume of distribution of the central
compartment, V2 apparent volume of distribution of the peripheral compartment, Vg
apparent volume of distribution of the CVF compartment
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Individual predicted concentrations vs. observed data graphs for efavirenz (a), atazanavir
(b), lamivudine (c) and tenofovir (d). The solid black line is the line of identity; blood
plasma concentrations are depicted with filled circles, while the cervicovaginal fluid
concentrations are depicted with open circles. 3TC lamivudine, ATV atazanavir, EFV
efavirenz, TFV tenofovir
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Visual predictive checks for efavirenz at each sampling period in both blood plasma and
cervicovaginal fluid using the 5th and 95th percentiles and median of 1,000 simulated
subjects and observed data at both first dose and multiple dose: a blood plasma at first dose;
b cervicovaginal fluid at first dose; c blood plasma at multiple dose; d cervicovaginal fluid
at multiple dose. BP blood plasma, CVF cervicovaginal fluid, EFV efavirenz
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Visual predictive checks for atazanavir at each sampling period in both blood plasma and
cervicovaginal fluid using the 5th and 95th percentiles and median of 1,000 simulated
subjects and observed data at both first dose and multiple dose: a blood plasma at first dose;
b cervicovaginal fluid at first dose; c blood plasma at multiple dose; d cervicovaginal fluid
at multiple dose. ATV atazanavir, BP blood plasma, CVF cervicovaginal fluid
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Visual predictive checks for lamivudine administered at 300 mg daily at each sampling
period in both blood plasma and cervicovaginal fluid using the 5th and 95th percentiles and
median of 1,000 simulated subjects and observed data at both first dose and multiple dose: a
blood plasma at first dose; b cervicovaginal fluid at first dose; c blood plasma at multiple
dose; d cervicovaginal fluid at multiple dose. 3TC lamivudine, BP blood plasma, CVF
cervicovaginal fluid
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Visual predictive checks for tenofovir at each sampling period in both blood plasma and
cervicovaginal fluid using the 5th and 95th percentiles and median of 1,000 simulated
subjects and observed data at both first dose and multiple dose: a blood plasma at first dose;
b cervicovaginal fluid at first dose; c blood plasma at multiple dose; d cervicovaginal fluid
at multiple dose. BP blood plasma, CVF cervicovaginal fluid, TFV tenofovir
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